| 标题 |
 Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊：Lancet 作者：Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Peña AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M, CheckMate 9DW investigators 出版日期：2025-05-08 |
| 求助人 | |
| 下载 | 求助已完成，仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)
Nole
张欢馨
cdercder
yjh123
东方元语
1104481279
OK
Kao
xing_xing
行走的荷尔蒙
woshi123
科研狗
aajhajkahna
ddd
飞快的慕山
Criminology34
ming2026
OCDer
天晴
学术文献互助
皖公网安备34019202002308
